Literature DB >> 17386925

Role of tumor invasiveness, the extracellular matrix, and chromatin sequestration in the susceptibility of uveal melanoma to herpes simplex virus type 1.

Klara Valyi-Nagy1, Robert Folberg, Tibor Valyi-Nagy, Andrew J Maniotis.   

Abstract

To better understand determinants of susceptibility/resistance of uveal melanomas to herpes simplex virus type 1 (HSV-1) oncolytic therapy, uveal melanoma cell lines of low (OCM1a) and of high (M619, MUM2B) invasive potential were infected with HSV-1 either in the presence or absence of a laminin-rich extracellular matrix (Matrigel). OCM1a cultures were destroyed faster by HSV-1 than M619 and MUM2B cultures. In the presence of Matrigel, all melanoma cultures demonstrated delayed destruction by HSV-1 relative to Matrigel-free cultures. As sequestration of chromatin is a characteristic feature of highly invasive uveal melanomas that is further increased by exposure to laminin, we explored whether chromatin sequestration could be reversed by HSV-1 infection. HSV-1 infection induced a global reversal of chromatin sequestration in highly invasive uveal melanoma cells. However, this viral effect was first observed only 2h following virus infection and required novel protein synthesis from input viral DNA. These findings suggest that tumor invasiveness, the spatial relationship of tumor cells to laminin and chromatin sequestration are determinants of susceptibility/resistance of melanomas to HSV-1 oncolytic therapy. Furthermore, these findings indicate for the first time that HSV-1 infection is associated with global exposure of normally highly sequestered cellular DNA in malignant cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17386925      PMCID: PMC1950675          DOI: 10.1016/j.exer.2007.01.023

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  37 in total

1.  Global analysis of herpes simplex virus type 1 transcription using an oligonucleotide-based DNA microarray.

Authors:  S W Stingley; J J Ramirez; S A Aguilar; K Simmen; R M Sandri-Goldin; P Ghazal; E K Wagner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  The patterns of accumulation of cellular RNAs in cells infected with a wild-type and a mutant herpes simplex virus 1 lacking the virion host shutoff gene.

Authors:  Brunella Taddeo; Audrey Esclatine; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-12       Impact factor: 11.205

Review 3.  From existing therapies to novel targets: a current view on melanoma.

Authors:  Jin Namkoong; Jeffrey J Martino; Suzie Chen
Journal:  Front Biosci       Date:  2006-09-01

4.  Intralesional injection of herpes simplex virus 1716 in metastatic melanoma.

Authors:  R M MacKie; B Stewart; S M Brown
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

Review 5.  Uveal melanoma: natural history and treatment options for metastatic disease.

Authors:  E Wöll; A Bedikian; S S Legha
Journal:  Melanoma Res       Date:  1999-12       Impact factor: 3.599

Review 6.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

7.  Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns.

Authors:  Robert Folberg; Zarema Arbieva; Jonas Moses; Amin Hayee; Tone Sandal; Shrihari Kadkol; Amy Y Lin; Klara Valyi-Nagy; Suman Setty; Lu Leach; Patricia Chévez-Barrios; Peter Larsen; Dibyen Majumdar; Jacob Pe'er; Andrew J Maniotis
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

8.  Expression of herpes simplex virus type 2 US3 affects the Cdc42/Rac pathway and attenuates c-Jun N-terminal kinase activation.

Authors:  T Murata; F Goshima; T Daikoku; H Takakuwa; Y Nishiyama
Journal:  Genes Cells       Date:  2000-12       Impact factor: 1.891

Review 9.  Viral induction of site-specific chromosome damage.

Authors:  Elizabeth A Fortunato; Deborah H Spector
Journal:  Rev Med Virol       Date:  2003 Jan-Feb       Impact factor: 6.989

Review 10.  Oncolytic herpes simplex virus vectors for cancer virotherapy.

Authors:  Susan Varghese; Samuel D Rabkin
Journal:  Cancer Gene Ther       Date:  2002-12       Impact factor: 5.987

View more
  5 in total

Review 1.  Authenticating cell lines in ophthalmic research laboratories.

Authors:  Robert Folberg; Shrihari S Kadkol; Shahar Frenkel; Klara Valyi-Nagy; Martine J Jager; Jacob Pe'er; Andrew J Maniotis
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-08       Impact factor: 4.799

2.  Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures.

Authors:  Klara Valyi-Nagy; Bernadett Kormos; Mohamed Ali; Deepak Shukla; Tibor Valyi-Nagy
Journal:  Mol Vis       Date:  2012-03-02       Impact factor: 2.367

3.  Increased Resistance of Breast, Prostate, and Embryonic Carcinoma Cells against Herpes Simplex Virus in Three-Dimensional Cultures.

Authors:  Andras Voros; Bernadett Kormos; Tibor Valyi-Nagy; Klara Valyi-Nagy
Journal:  ISRN Oncol       Date:  2013-12-22

4.  Herpes simplex encephalitis is linked with selective mitochondrial damage; a post-mortem and in vitro study.

Authors:  Małgorzata Wnęk; Lorenzo Ressel; Emanuele Ricci; Carmen Rodriguez-Martinez; Julio Cesar Villalvazo Guerrero; Zarini Ismail; Colin Smith; Anja Kipar; Beate Sodeik; Patrick F Chinnery; Tom Solomon; Michael J Griffiths
Journal:  Acta Neuropathol       Date:  2016-07-25       Impact factor: 17.088

5.  Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures.

Authors:  Tibor Valyi-Nagy; Brian Fredericks; Aditya Ravindra; James Hopkins; Deepak Shukla; Klara Valyi-Nagy
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.